TERT Promoter Mutations for the Early Detection and Monitoring of Ubladder Cancers

Sept. 24, 2015

TERT Promoter Mutations for the Early Detection and Monitoring of Ubladder Cancers

Technology description

Invention novelty
This invention is a method for a noninvasive, urine-based, bladder cancer diagnostic and/or monitoring tool.

Technical Details

Johns Hopkins researchers previously discovered TERT promoter mutations (C12506), in a variety of cancers. For this current technology they detected TERT promoter mutations in urine samples specifically from patients with reoccurring bladder cancer, but not in non-recurring patients.

Data Availability: Under CDA/NDA

Publication(s)/Associated Cases: Killela, PJ et al. 2013 ;

Categories: Diagnostic

Keywords: bladder, cancer, TERT promoter, hTERT, TRT, hTRT, biomarker, diagnostic, monitoring,

Advantages

Bladder cancer diagnosis and monitoring is mainly achieved by cystoscopy, a highly invasive procedure. While a number of FDA-approved urine-based bladder cancer diagnostics exist, they are not widely used in the clinical setting due to inconsistent results. This current technology is advantageous because;

- Unlike cystoscopy, it is a noninvasive diagnostic.

- Could potentially detect bladder cancer at a higher sensitivity and/or specificity than current urine-based tests.

由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。

More information

Institution

Johns Hopkins University

Keywords:

urine samples specifically

reoccurring bladder cancer

下载 PDF 文档

Technologies